BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 24813528)

  • 1. Epigenetic deregulation in myeloid malignancies.
    Meldi KM; Figueroa ME
    Transl Res; 2015 Jan; 165(1):102-14. PubMed ID: 24813528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
    Lowder JN; Taverna P; Issa JP
    Epigenomics; 2015 Oct; 7(7):1083-8. PubMed ID: 26541345
    [No Abstract]   [Full Text] [Related]  

  • 3. Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias.
    Leone G; D'Alò F; Zardo G; Voso MT; Nervi C
    Curr Med Chem; 2008; 15(13):1274-87. PubMed ID: 18537607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes.
    Khan H; Vale C; Bhagat T; Verma A
    Semin Hematol; 2013 Jan; 50(1):16-37. PubMed ID: 23507481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic regulators and their impact on therapy in acute myeloid leukemia.
    Pastore F; Levine RL
    Haematologica; 2016 Mar; 101(3):269-78. PubMed ID: 26928248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Digging deep into "dirty" drugs - modulation of the methylation machinery.
    Pleyer L; Greil R
    Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Epigenetic therapy in myelodysplastic syndromes (MDS). Treatment with DNA methyltransferase inhibitors].
    Daskalakis M; Blagitko-Dorfs N; Hackanson B; Lübbert M
    Pharm Unserer Zeit; 2010 May; 39(3):217-27. PubMed ID: 20425776
    [No Abstract]   [Full Text] [Related]  

  • 8. Myelodysplastic syndromes (MDSs) and acute myelogenous leukemia (AML) comprise a closely linked continuum of malignant hematologic diseases. Introduction.
    Baylin SB; Mufti GJ
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S1-3. PubMed ID: 16341235
    [No Abstract]   [Full Text] [Related]  

  • 9. Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.
    Hou HA; Tien HF
    Expert Rev Hematol; 2016 May; 9(5):447-69. PubMed ID: 26789100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic therapies in MDS and AML.
    Griffiths EA; Gore SD
    Adv Exp Med Biol; 2013; 754():253-83. PubMed ID: 22956506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
    Stahl M; Gore SD; Vey N; Prebet T
    Expert Opin Investig Drugs; 2016; 25(3):307-17. PubMed ID: 26807602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
    Jhanwar SC
    Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors.
    Ungerstedt JS
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30304859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic manipulation of the immune response: a novel treatment strategy in hematologic malignancies.
    Craddock C
    Cytotherapy; 2011 May; 13(5):516-7. PubMed ID: 21375421
    [No Abstract]   [Full Text] [Related]  

  • 15. The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia.
    Gonzalez-Lugo JD; Chakraborty S; Verma A; Shastri A
    Semin Hematol; 2021 Jan; 58(1):56-65. PubMed ID: 33509444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting DNA hypermethylation: Computational modeling of DNA demethylation treatment of acute myeloid leukemia.
    Przybilla J; Hopp L; Lübbert M; Loeffler M; Galle J
    Epigenetics; 2017; 12(10):886-896. PubMed ID: 28758855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia.
    Voso MT; Lo-Coco F; Fianchi L
    Curr Opin Oncol; 2015 Nov; 27(6):532-9. PubMed ID: 26352541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
    Estey EH
    Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancer DNA methylation in acute myeloid leukemia and myelodysplastic syndromes.
    Benetatos L; Vartholomatos G
    Cell Mol Life Sci; 2018 Jun; 75(11):1999-2009. PubMed ID: 29484447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: achievements and challenges.
    Lübbert M; Kuendgen A
    Cancer; 2015 Feb; 121(4):498-501. PubMed ID: 25336205
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.